Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals. More recently, Biocon’s biosimilar insulin Glargine made at Malaysia received a historic the U.S. FDA approval as the ‘first interchangeable biosimilar’.

Through the insulins manufactured at this facility, Biocon Sdn Bhd is also making a difference to the lives of millions of people with diabetes worldwide by providing them access to affordable life-saving insulin therapy.

The scientifically validated, high quality human insulin and analog products manufactured at the facility in Johor, Malaysia, are benefiting patients in many developed markets like the U.S., EU, Australia, as well as many emerging market countries in the Middle East and Latin America.